Get the app
NSEHealthcare

Syncom Formulations (India) Limited (SYNCOMF)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹18.78+2.01%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹126 cr
Revenue YoY
+7.4%
Net profit
₹25 cr
Profit YoY
+57.7%
Net margin
19.8%

Key statistics

Market cap
₹1,742 cr
P/E
20.6
Forward P/E
0.0
P/B
4.41
Book value
₹4.45
EPS (TTM)
₹0.90
52-week high
₹22.59
52-week low
₹10.21
50-day MA
₹15.62
200-day MA
₹14.03
Beta
0.80

Shareholding

Promoters
50.57%
Institutions
0.13%

Recent filings & reports

DocumentDate
Quarterly results · Q1 FY27
SYNCOM FORMULATIONS (INDIA) LIMITED Q1 FY2026-27 FINANCIAL RESULTS SUMMARY --- HEADLINE NUMBERS • Q1 FY2026-27 Standalone Revenue from Operations:
2026-08-11
Quarterly results · Q4 FY26
SYNCOM FORMULATIONS (INDIA) LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: Rs 48,657.28 lacs (up from Rs 46,284.
2026-05-22
Quarterly results · Q3 FY26
SYNCOM FORMULATIONS (INDIA) LIMITED – FINANCIAL SUMMARY 9 Months ended 31st December 2025 --- HEADLINE NUMBERS • Revenue from Operations (9M FY26):
2026-02-12
Quarterly results · Q2 FY26
SYNCOM FORMULATIONS (INDIA) LIMITED - H1 FY2025-26 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2025-26 Revenue from Operations: Rs 12,143.51 lakhs (St
2025-11-12
Annual report FY2025
SYNCOM FORMULATIONS (INDIA) LIMITED – ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Company: Syncom Formulations (India) Limited – pharmaceutical
2025-09-04
Quarterly results · Q1 FY26
SYNCOM FORMULATIONS (INDIA) LIMITED – Q1 FY2025-26 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 FY2025-26 (Quarter ended 30 June 2025) Standalone Results
2025-08-08
Quarterly results2025-02-10
Quarterly results2024-11-11

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Syncom Formulations (India) Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.